Etomidate was synthesized in 1964 by Janssen in Belgium. It is a carboxylated imidazole derivative, R-(+)-ethyl 1-(alphamethylbenzyl)-1H-imidazole-5-carboxylate. Animal studies in the early 1970s suggested that it was a useful and potent intravenous induction agent. In animals it was discovered that the duration of hypnosis was directly related to the dose administered, i.e. double the dose would double the duration of action.
Clinical trials were begun in 1972 by A Doenicke. "After the necessary precautionary measures (checks on EEG and ECG) the hypnotic was first administered to a patient on March 21, 1972. Intra-arterial blood pressure, heart rate and respiration were checked constantly. For obvious reasons the dosage selected at that time was low. The effect was just sufficient for a minor operation to be performed as an outpatient. No significant influence on the cardiovascular system or respiration was observed." They continued their research with another 25 unselected patients and did not encounter any problems.
Having established its clinical effectiveness, Doenicke then conducted further studies on volunteers to measure histamine release. Their initial conclusion was that etomidate did not cause any histamine release. Further clinical investigations confirmed these findings: "On the basis of existing experimental investigations and of our own clinical observations in 2,500 cases we may assume that etomidate is the first intravenous hypnotic that does not cause release of histamine. Such a statement should be accepted with caution, however, from a prognostic point of view, because sensitisation after repeated application or the release of histamine under certain conditions (e.g. activation of the complement system) cannot yet be excluded." The only significant problem they reported was a high incidence of myoclonic movements. These were reduced by benzodiazepine premedication but at the expense of prolonged recovery.
At the conclusion of these early clinical trials, Doenicke and his colleagues had conducted nearly 7000 clinical anaesthetics with etomidate "without any complications". They concluded: "0.30 mg etomidate is more active than 5 mg thiopental" and "etomidate, as a hypnotic, is superior to barbiturates as well as to flunitrazepam."
Chiu and Van compared etomidate and thiopentone in 1978. They found a similar onset time but a marked delay in the loss of the eyelash reflex with etomidate, some patients retaining this reflex throughout the procedure. Sixty-eight per cent of the etomidate patients had involuntary movements either frankly convulsive or jerky limb movements. Simple acts like inflation of the blood pressure cuff were enough to stimulate further involuntary movement. Other excitatory phenomena such as hiccups and laryngospasm were not significantly different between the groups. The other marked difference was a high incidence of pain on injection in the etomidate group which many patients found distressing.
Etomidate is a water-soluble substance but is unstable in this form. Consequently it was dissolved in propylene glycol, a solvent well known to cause pain on injection. These complications, pain on injection and involuntary movements, could be reduced by premedication with opioids and benzodiazepines. A number of studies also reported a high incidence of nausea and vomiting. Accordingly, etomidate never gained wide acceptance as an induction agent and was generally reserved for situations where the cardiovascular stability and lack of histamine release were seen to be advantageous. However, the pharmacokinetics of etomidate led to its widespread use as an infusion for sedation in intensive care in the early 1980s.
Then, in 1983, Ledingham and Watt from Glasgow suggested that etomidate infusion was leading to increased mortality in intensive care patients. They suggested that this was due to adrenocortical suppression. The report was sufficiently alarming to cause the U.K. Committee on the Safety of Medicines to write to all U.K. doctors about the potential problem with etomidate.
Ledingham and Watt conducted a retrospective survey of their intensive care unit and discovered that the introduction of etomidate infusions increased the mortality significantly. In 1979-1980 most patients were sedated with benzodiazepines and the death rate was 25%. Over the next two years, etomidate infusions were used extensively and the death rate increased to 44% although the mean Injury Severity Score was constant over the four years. The cause of death was usually infection and led to the suspicion that adrenocortical suppression was contributory.
An editorial in the British Journal of Anaesthesia in 1984 reported in vitro studies confirming that etomidate did inhibit steroid synthesis. The concentration required was below that reached with clinical infusions. It was also suggested that, in intensive care, there are other factors which can decrease etomidate clearance and raise the level further, such as interactions with other drugs, mainly opioids, and effects on liver clearance.
Subsequent studies confirmed the fact that etomidate infusion inhibits mitochondrial hydroxylase activity, thus decreasing the production of cortisol and corticosterone derivatives. In animal studies the stress response to haemorrhagic shock was also lost. Initially it was suggested that this response was confined to patients receiving infusions. However, in 1984, Robert Fragen and colleagues studied several patients having minor gynaecological procedures and discovered suppression of the stress response to surgery in patients who had an etomidate induction. This effect lasted several hours.
Etomidate therefore enjoyed only a brief career as an infusion agent although initially it seemed to have ideal characteristics. Its popularity as an induction agent was limited more by its tendency to cause myoclonic movements, pain on injection and postoperative nausea and vomiting. It is still available in Europe but has limited application. CHRISTINE BALL, ROD WESTHORPE Geoffrey Kaye Museum of Anaesthetic History
